RE49773 | Hybrid felts of electrospun nanofibers | May 18, 21 | Jan 02, 24 | NANOPAREIL, LLC |
RE49625 | Nanoscale process to generate reagents selective for individual protein variants | Apr 10, 20 | Aug 29, 23 | Arizona Board of Regents a body corporate of the State of Arizona acting for and on behalf of Arizona State University |
RE49495 | Binding polypeptides having a mutated scaffold | Apr 06, 20 | Apr 18, 23 | Affibody AB |
RE49435 | Glycan-interacting compounds and methods of use | Jan 29, 20 | Feb 28, 23 | SEAGEN INC. |
RE49339 | Antibodies to the C3D fragment of complement component 3 | Apr 10, 19 | Dec 20, 22 | The Regents of the University of Colorado a Body Corporate; Musc Foundation for Research Development; |
RE49280 | TGFbeta type II-type III receptor fusions | Apr 04, 19 | Nov 08, 22 | 501 Board of Regents The University of Texas System |
RE49251 | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof | Mar 26, 21 | Oct 18, 22 | MAPI PHARMA LTD. |
RE49192 | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile | May 30, 19 | Aug 30, 22 | INTERNATIONAL—DRUG—DEVELOPMENT BIOTECH |
RE49099 | Humanized monoclonal antibodies against activated protein c and uses thereof | May 22, 19 | Jun 07, 22 | Bayer Healthcare LLC |
RE49076 | Compositions and methods for treating renal disease | Jul 23, 19 | May 17, 22 | Beth Israel Deaconess Medical Center, Inc. |
RE49037 | Broadly neutralizing antibody and uses thereof | Dec 24, 19 | Apr 19, 22 | International Aids Vaccine Initiative; The Scripps Research Institute; Cornell University; |
RE49026 | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof | Oct 06, 17 | Apr 12, 22 | MEDICAL DIAGNOSTIC LABORATORIES, LLC |
RE48959 | Humanized antibodies to LIV-1 and use of same to treat cancer | Jan 04, 18 | Mar 08, 22 | SEAGEN INC. |
RE48899 | Slanted FBG for SRS suppression | Apr 25, 19 | Jan 25, 22 | nLIGHT, Inc. |
RE48890 | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation | Feb 22, 19 | Jan 11, 22 | Celgene Corporation |
RE48863 | toxin and methods thereof | Apr 18, 19 | Dec 28, 21 | Wyeth LLC |
RE48862 | toxin and methods thereof | Apr 18, 19 | Dec 28, 21 | Wyeth LLC |
RE48805 | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein | Feb 12, 19 | Nov 02, 21 | Vision Global Holdings Ltd. |
RE48787 | Humanised antibodies | Apr 09, 19 | Oct 26, 21 | UCB Biopharma SRL |
RE48751 | Immunoconjugates with an intracellularly-cleavable linkage | Dec 12, 18 | Sep 28, 21 | Immunomedics, Inc. |